Analysts’ expectations for the coming year seems relatively unexciting, with earnings continuing to flop around in the negative territory, reaching $-30.2M in 2019. Additionally, earnings are predicted to fall further in the following year, declining to $-41.6M in 2020 and $-58.8M in 2021.
Even though it is helpful to be aware of the growth year by year relative to today’s figure, it may be more beneficial analyzing the rate at which the business is moving every year, on average. The advantage of this method is that we can get a better picture of the direction of GlycoMimetics’s earnings trajectory over the long run, irrespective of near term fluctuations, be more volatile. To calculate this rate, I’ve appended a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 31.89%. This means, we can expect GlycoMimetics will grow its earnings by 31.89% every year for the next couple of years.
For GlycoMimetics, there are three pertinent aspects you should further research:
1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
2. Valuation: What is GLYC worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether GLYC is currently mispriced by the market.
3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of GLYC? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!